Abstract
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS), in which inflammation develops upon leukocyte invasion into the CNS via the blood-brain barrier. α4-Integrin is an important cell adhesion molecule involved in the penetration process. Natalizumab is an α4-integrin-targeting monoclonal antibody that was recently approved for use as a disease-modifying therapy for MS in Japan. In this article, the mechanism of action, efficacy, and side effects of natalizumab will be reviewed.
| Original language | English |
|---|---|
| Pages (from-to) | 1149-1158 |
| Number of pages | 10 |
| Journal | Brain and Nerve |
| Volume | 66 |
| Issue number | 10 |
| Publication status | Published - 2014 Oct 1 |
Keywords
- Blood-brain barrier
- Multiple sclerosis
- Natalizumab
- Progressive multifocal leukoencephalopathy
- α 4-integrin
ASJC Scopus subject areas
- Clinical Neurology